Innate Pharma S.A is a biotechnology business based in the US. Innate Pharma S-A shares (IPHA) are listed on the NASDAQ and all prices are listed in US Dollars. Innate Pharma S-A employs 244 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Innate Pharma S-A
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – IPHA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Innate Pharma S-A stock price (NASDAQ: IPHA)Use our graph to track the performance of IPHA stocks over time.
Innate Pharma S-A shares at a glance
|Latest market close||$3.91|
|52-week range||$3.04 - $6.65|
|50-day moving average||$3.45|
|200-day moving average||$4.07|
|Wall St. target price||$7.19|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
Buy Innate Pharma S-A shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Innate Pharma S-A stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Innate Pharma S-A price performance over time
|1 week (2021-07-21)||N/A|
|1 month (2021-07-01)||9.83%|
|3 months (2021-04-30)||-7.78%|
|6 months (2021-01-28)||N/A|
|1 year (2020-07-28)||N/A|
|2 years (2019-07-28)||N/A|
|3 years (2018-07-28)||N/A|
|5 years (2016-07-28)||N/A|
Is Innate Pharma S-A under- or over-valued?
Valuing Innate Pharma S-A stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Innate Pharma S-A's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Innate Pharma S-A's EBITDA
Innate Pharma S-A's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $38.3 million.
The EBITDA is a measure of a Innate Pharma S-A's overall financial performance and is widely used to measure a its profitability.
Innate Pharma S-A financials
|Revenue TTM||$70.5 million|
|Gross profit TTM||$11.8 million|
|Return on assets TTM||-3.27%|
|Return on equity TTM||-34.27%|
|Market capitalisation||$262.4 million|
TTM: trailing 12 months
Shorting Innate Pharma S-A shares
There are currently 12,792 Innate Pharma S-A shares held short by investors – that's known as Innate Pharma S-A's "short interest". This figure is 98.8% up from 6,435 last month.
There are a few different ways that this level of interest in shorting Innate Pharma S-A shares can be evaluated.
Innate Pharma S-A's "short interest ratio" (SIR)
Innate Pharma S-A's "short interest ratio" (SIR) is the quantity of Innate Pharma S-A shares currently shorted divided by the average quantity of Innate Pharma S-A shares traded daily (recently around 31980). Innate Pharma S-A's SIR currently stands at 0.4. In other words for every 100,000 Innate Pharma S-A shares traded daily on the market, roughly 400 shares are currently held short.
However Innate Pharma S-A's short interest can also be evaluated against the total number of Innate Pharma S-A shares, or, against the total number of tradable Innate Pharma S-A shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Innate Pharma S-A's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Innate Pharma S-A shares in existence, roughly 0 shares are currently held short) or 0.0003% of the tradable shares (for every 100,000 tradable Innate Pharma S-A shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Innate Pharma S-A.
Find out more about how you can short Innate Pharma S-A stock.
Innate Pharma S-A share dividends
We're not expecting Innate Pharma S-A to pay a dividend over the next 12 months.
Innate Pharma S-A share price volatility
Over the last 12 months, Innate Pharma S-A's shares have ranged in value from as little as $3.04 up to $6.65. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Innate Pharma S-A's is 0.121. This would suggest that Innate Pharma S-A's shares are less volatile than average (for this exchange).
Innate Pharma S-A overview
Innate Pharma S. A. , a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; and IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway. Its products in preclinical trials include IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH61, NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, an anti-MICA/B antibody drug conjugate; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; Anti-Siglec-9, an antibody program; IPH25, a checkpoint inhibitor; and IPH62, an NKp46-NKCE platform. Innate Pharma S. A.
Innate Pharma S-A in the news
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
Number of Shares and Voting Rights of Innate Pharma as of July 1, 2021
Frequently asked questionsWhat percentage of Innate Pharma S-A is owned by insiders or institutions?
Currently 1.55% of Innate Pharma S-A shares are held by insiders and 0.378% by institutions. How many people work for Innate Pharma S-A?
Latest data suggests 244 work at Innate Pharma S-A. When does the fiscal year end for Innate Pharma S-A?
Innate Pharma S-A's fiscal year ends in December. Where is Innate Pharma S-A based?
Innate Pharma S-A's address is: 117, Avenue de Luminy, Marseille, France, 13009 What is Innate Pharma S-A's ISIN number?
Innate Pharma S-A's international securities identification number is: US45781K2042 What is Innate Pharma S-A's CUSIP number?
Innate Pharma S-A's Committee on Uniform Securities Identification Procedures number is: 45781K204
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert